FRAMINGHAM, MA--(MARKET WIRE)--Jun 19, 2007 -- Symbollon Pharmaceuticals, Inc. (OTC BB:SYMBA.OB - News) today announced the closing of patient enrollment in its IoGen(TM) Phase III pivotal trial. The study, being conducted by physicians throughout the U.S., is designed to evaluate the effectiveness of IoGen, a treatment which may be the first FDA-approved, non-hormonal therapy for moderate to severe cyclic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD).
